Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase

Slides:



Advertisements
Similar presentations
Molecular Therapy - Oncolytics
Advertisements

Molecular Therapy - Oncolytics
Molecular Therapy - Oncolytics
Jennifer R. Hamilton, Gayathri Vijayakumar, Peter Palese  Cell Reports 
Brian Hutzen, Chun-Yu Chen, Pin-Yi Wang, Les Sprague, Hayley M
Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus  Johanna K. Kaufmann, Sascha Bossow, Christian Grossardt, Stefanie.
Molecular Therapy - Methods & Clinical Development
Recombinant mumps virus as a cancer therapeutic agent
Volume 15, Issue 12, Pages (December 2007)
Molecular Therapy - Oncolytics
Volume 10, Issue 5, Pages (November 2004)
Molecular Therapy - Oncolytics
Volume 24, Issue 12, Pages (December 2016)
Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity  Tina.
Volume 17, Issue 1, Pages (January 2010)
Molecular Therapy - Oncolytics
Lukkana Suksanpaisan, Rong Xu, Mulu Z
Molecular Therapy - Oncolytics
Paola Zigrino, Isolde Kuhn, Tobias Bäuerle, Jan Zamek, Jay W
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
Volume 7, Issue 1, Pages (January 2003)
Molecular Therapy - Oncolytics
Volume 18, Issue 9, Pages (September 2010)
The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF  Kathrin Schwager, Teresa Hemmerle, David Aebischer,
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Oncolytics
Volume 22, Issue 1, Pages (January 2014)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Volume 17, Issue 1, Pages (January 2010)
Volume 9, Issue 6, Pages (June 2004)
Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression  Shawn T. Beug, Stephanie J. Pichette,
Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models  Fabrice Le Boeuf, Simon Gebremeskel,
Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma  Muneyoshi Futami, Kota Sato, Kanji Miyazaki, Kenshi.
Volume 23, Issue 4, Pages (April 2015)
Volume 23, Issue 4, Pages (April 2015)
Volume 12, Issue 5, Pages (November 2005)
Melissa B. Uccellini, Adolfo García-Sastre  Cell Reports 
Volume 20, Issue 1, Pages (January 2012)
Lukxmi Balathasan, Vera A
Volume 24, Issue 1, Pages (January 2016)
Elizabeth M Hadac, Elizabeth J Kelly, Stephen J Russell 
Sangeet Lal, Corey Raffel  Molecular Therapy - Oncolytics 
Volume 18, Issue 5, Pages (May 2010)
Volume 18, Issue 12, Pages (December 2010)
Molecular Therapy - Oncolytics
Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine  Eike Binz, Susanne.
Molecular Therapy - Oncolytics
Anisha Gupta, Elias Quijano, Yanfeng Liu, Raman Bahal, Susan E
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002  Eric K. Ring, Rong Li, Blake P. Moore,
Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells
Volume 10, Issue 6, Pages (December 2004)
Molecular Therapy - Oncolytics
Therapeutic Efficacy of G207, a Conditionally Replicating Herpes Simplex Virus Type 1 Mutant, for Gallbladder Carcinoma in Immunocompetent Hamsters  Kenji.
Volume 26, Issue 4, Pages (April 2018)
Volume 20, Issue 4, Pages (April 2012)
Molecular Therapy - Oncolytics
Cowpox Virus: A New and Armed Oncolytic Poxvirus
Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis  Yu Sakurai, Tomoya.
Molecular Therapy - Oncolytics
Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways  Ernesto Mejías-Pérez,
Synergistic combination of valproic acid and oncolytic parvovirus H‐1PV as a potential therapy against cervical and pancreatic carcinomas H‐1PV/VPA co‐treatment.
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism  Johann Foloppe, Juliette.
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus  Riikka Havunen, João M. Santos, Suvi Sorsa, Tommi Rantapero,
Volume 16, Issue 10, Pages (October 2008)
Volume 20, Issue 6, Pages (June 2012)
Volume 20, Issue 4, Pages (April 2012)
Molecular Therapy - Oncolytics
Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy  Adrian Pelin, Johann Foloppe, Julia Petryk, Ragunath.
Molecular Therapy - Oncolytics
Volume 12, Issue 5, Pages (November 2005)
Presentation transcript:

Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase Irina Kuznetsova, Tobias Arnold, Thomas Aschacher, Cornelia Schwager, Balazs Hegedus, Tamas Garay, Marina Stukova, Maria Pisareva, Stephan Pleschka, Michael Bergmann, Andrej Egorov  Molecular Therapy - Oncolytics  Volume 7, Pages 37-44 (December 2017) DOI: 10.1016/j.omto.2017.09.002 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Schematic Representation of Modifications in the HA Cleavage Site The cleavage site is indicated by bold letters. The amino acids changed during adaptation to elastase are shown in red. Molecular Therapy - Oncolytics 2017 7, 37-44DOI: (10.1016/j.omto.2017.09.002) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Growth Kinetic of Modified NS116-GFP/AE Virus A 24-hr-old monolayer of Vero cells was infected with NS116-GFP/AE virus in the presence of either pancreatic elastase (p-elastase) or neutrophil elastase (n-elastase). A viral titer was determined by TCID50 in Vero cells at the indicated time points + SEM (n = 6). Molecular Therapy - Oncolytics 2017 7, 37-44DOI: (10.1016/j.omto.2017.09.002) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Growth Properties of NS116-GFP/AE and NS116-GFP/AT Virus in Vero Cells in Co-culture System with Human Neutrophils or Supernatant Supplemented with Neutrophil Elastase or Trypsin (A) Vero cells were infected at an MOI of 0.01 under indicated condition and viral titer was determined by TCID50 24 hr post-infection. Data represent means + SEM (n = 3). (B) Virus induced GFP expression, which indicates viral growth. The pictures of infected Vero cells were taken 48 hr post-infection using an AxioCam ICc3 Rev.2-3 camera, with a magnification of 200×. Experiments were carried out three times with neutrophils of another proband, and the corresponding results are provided. Scale bar, 100 μm. Molecular Therapy - Oncolytics 2017 7, 37-44DOI: (10.1016/j.omto.2017.09.002) Copyright © 2017 The Authors Terms and Conditions

Figure 4 Growth of NS116-GFP/AT and NS116-GFP/AE Viruses in Different Cell Lines Vero, B16f1, PANC-1, A375, or CaCo2 1 × 105 cells were infected with either NS116-GFP/AT or NS116-GFP/AE viruses at an MOI of 0.01 and cultivated in the presence trypsin or neutrophil elastase, respectively. Supernatant was collected 12, 24, 48, and 72 hr post-infection. Data represent means + SEM (n = 3). Molecular Therapy - Oncolytics 2017 7, 37-44DOI: (10.1016/j.omto.2017.09.002) Copyright © 2017 The Authors Terms and Conditions

Figure 5 Effect of NS116-GFP/AT and NS116-GFP/AE Treatment on the Survival of B16f1 Melanoma- and PANC-1-Bearing Mice (A and B) Seven 6-week-old C57/BL6 or athymic nude mice were subcutaneously injected with B16f1 (A) or PANC-1 (B) cells. 5 days after implantation of melanoma cells and 10 days after implantation of pancreatic adenocarcinoma cells, the treatment with either NS116-GFP/AT and NS116-GFP/AE virus was started with the intratumoral injection of 1 × 107 TCID50/mouse. Treatment was repeated on days 7, 9, 11, and 13 for C57/BL6 mice and on days 12, 14, 16, and 18 for PANC-1-bearing mice. The dose of the oncolytic virus was increased up to 1 × 108 TCID50 /mouse for the last two injections. Mice were sacrificed when tumor volumes reached 2000 mm3. ns, not significant. *p < 0.05, **p < 0.01. Molecular Therapy - Oncolytics 2017 7, 37-44DOI: (10.1016/j.omto.2017.09.002) Copyright © 2017 The Authors Terms and Conditions

Figure 6 Detection of Viral Proteins and Neutrophil Infiltration in Tumor Tissue 2, 4, and 7 days after the first injection of either NS116-GFP/AT or NS116-GFP/AE virus, PANC-1 tumors were extracted and fixed in 3.7% formaldehyde. Immunohistochemical staining of de-paraffinized sections was performed using anti-hemagglutinin antibody (blue), anti-neutrophil antibody (green), anti-cytokeratin-7 antibody (as a marker of PANC-1 cells) (red), and DNA dye DRAQ5 (yellow). Scale bar, 20 μm. Molecular Therapy - Oncolytics 2017 7, 37-44DOI: (10.1016/j.omto.2017.09.002) Copyright © 2017 The Authors Terms and Conditions